Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 3-Aminobenzamide (PARP-IN-1): Benchmarks in Poly(ADP-ribo...

    2026-01-15

    3-Aminobenzamide (PARP-IN-1): Benchmarks in Poly(ADP-ribose) Polymerase Inhibition

    Executive Summary: 3-Aminobenzamide (PARP-IN-1) is a potent, cell-permeable inhibitor of poly(ADP-ribose) polymerase (PARP), showing an IC50 of approximately 50 nM in Chinese hamster ovary (CHO) cells (https://www.apexbt.com/ino-1001.html). It achieves >95% PARP activity inhibition above 1 μM with negligible toxicity under standard culture conditions. The compound improves endothelial function by enhancing nitric oxide-mediated vasorelaxation after oxidative challenge (Grunewald et al. 2019, https://doi.org/10.1371/journal.ppat.1007756). In diabetic mouse models, it reduces mesangial expansion and podocyte loss, demonstrating translational value in nephropathy research. APExBIO supplies this compound as SKU A4161, supporting reproducible PARP inhibition workflows.

    Biological Rationale

    Poly(ADP-ribose) polymerases (PARPs) function as key mediators of ADP-ribosylation, a post-translational modification critical for DNA repair, cellular stress responses, and host-pathogen interactions (Grunewald et al., 2019). Humans encode at least 17 PARPs; PARP1 and PARP2 account for the majority of nuclear PARylation activity. PARP overactivation can deplete NAD+ and ATP pools, leading to cell dysfunction or death, particularly under oxidative stress or DNA-damaging conditions. Inhibition of PARP enzymatic activity has translational utility in oncology, neuroprotection, cardiovascular, and renal disease models. 3-Aminobenzamide (PARP-IN-1) has emerged as a gold-standard tool for dissecting the functional consequences of PARP inhibition in both basic and translational research (APExBIO).

    Mechanism of Action of 3-Aminobenzamide (PARP-IN-1)

    3-Aminobenzamide (PARP-IN-1) operates as a competitive inhibitor of NAD+ binding to the catalytic site of PARP enzymes. By occupying the active site, it prevents the transfer of ADP-ribose units to target proteins, thereby inhibiting both mono- and poly-ADP-ribosylation reactions. The inhibition is rapid, dose-dependent, and reversible. In CHO cell-based assays, the IC50 is approximately 50 nM, with >95% enzymatic inhibition observed at concentrations above 1 μM. Importantly, 3-Aminobenzamide does not significantly affect cell viability at effective concentrations, as shown in multiple model systems (APExBIO).

    Evidence & Benchmarks

    • 3-Aminobenzamide inhibits PARP activity in CHO cells with an IC50 of ~50 nM under standard culture conditions (APExBIO).
    • >95% inhibition of PARP is achieved at >1 μM, with no significant cytotoxicity (APExBIO).
    • In oxidant-induced myocyte dysfunction models, 3-Aminobenzamide blocks PARP-mediated effects and preserves contractile function (DOI:10.1371/journal.ppat.1007756).
    • The compound enhances acetylcholine-induced, endothelium-dependent, nitric oxide-mediated vasorelaxation post hydrogen peroxide stress (DOI:10.1371/journal.ppat.1007756).
    • In diabetic db/db mouse models, it reduces albumin excretion, mesangial expansion, and podocyte depletion, supporting its use in diabetic nephropathy research (APExBIO).
    • PARP inhibition by 3-Aminobenzamide can enhance viral replication in host-pathogen models by suppressing interferon production, underscoring the role of PARPs in innate immunity (DOI:10.1371/journal.ppat.1007756).

    This article updates and clarifies the translational scope outlined in "Translational Leverage of 3-Aminobenzamide (PARP-IN-1)" by focusing on direct assay parameters and disease model outcomes. For an integrated comparison of workflow strategies, see "Translational Leverage with 3-Aminobenzamide (PARP-IN-1)", which emphasizes experimental design guidance. For mechanistic frontiers, this article extends the present benchmarks with future-facing perspectives.

    Applications, Limits & Misconceptions

    Applications:

    • PARP Activity Inhibition Assays: Gold-standard for in vitro and cell-based measurement of PARP enzymatic suppression.
    • Oxidative Stress Models: Used to dissect the role of PARP in myocyte and endothelial dysfunction post oxidant insult.
    • Diabetic Nephropathy: Demonstrates efficacy in reducing hallmark features of diabetic kidney injury in db/db mice.
    • Host-Pathogen Studies: Tool for evaluating the role of PARPs in antiviral immunity and interferon regulation (DOI:10.1371/journal.ppat.1007756).

    Common Pitfalls or Misconceptions

    • Not isoform-selective: 3-Aminobenzamide is a pan-PARP inhibitor and does not discriminate between PARP family members.
    • Does not reverse existing ADP-ribosylation: It prevents new PARP activity but does not remove previous modifications.
    • Limited clinical translation: The compound is for research use only; it is not suitable for diagnostic or therapeutic use.
    • Ineffective in absence of PARP activity: Has no effect if the target system lacks PARP expression or activity.
    • Stability issues: Long-term storage of dissolved compound is not recommended; best stored as a solid at -20°C (APExBIO).

    Workflow Integration & Parameters

    Physical Properties: 3-Aminobenzamide (C7H8N2O, MW 136.15, CAS 3544-24-9) is a solid compound. Solubility is ≥23.45 mg/mL in water (ultrasonic assistance), ≥48.1 mg/mL in ethanol, and ≥7.35 mg/mL in DMSO. Solutions should be freshly prepared and not stored long-term. Store the solid at -20°C for maximum stability. Shipments from APExBIO are on Blue Ice.

    Experimental Use: For PARP inhibition in CHO cells, begin with a concentration range of 10–1000 nM to optimize IC50 measurement. In disease models, effective concentrations are typically 1–10 μM, but titration and toxicity controls are essential. For mechanistic studies in oxidative stress, pre-treat cells or tissues for 30–60 minutes prior to insult. Review the detailed workflow integration guide for stepwise protocols and benchmarking tips.

    Conclusion & Outlook

    3-Aminobenzamide (PARP-IN-1) remains a cornerstone in the study of poly(ADP-ribose) polymerase inhibition due to its potency, predictability, and broad utility (APExBIO). Its use has clarified the roles of PARPs in DNA repair, oxidative injury, vascular biology, and immunity. Ongoing research leverages this compound in translational settings, particularly for modeling diabetic nephropathy and investigating host-virus interactions. For deeper strategic guidance on next-generation PARP inhibitors and experimental design, refer to recent thought-leadership content on mechanistic frontiers.